<DOC>
	<DOCNO>NCT01972724</DOCNO>
	<brief_summary>The purpose study evaluate efficacy pioglitazone 30 mg glycemic control use patient inadequately control type 2 diabetes mellitus treat fixed combination metformin sulfonylurea .</brief_summary>
	<brief_title>Efficacy Pioglitazone Patients With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy</brief_title>
	<detailed_description>The drug test study call pioglitazone . Pioglitazone test treat glycemic control adult inadequately control type 2 diabetes mellitus . This study look glycemic control people take triple oral therapy metformin , sulfonylurea , pioglitazone 15 mg . The study enroll approximately 114 patient . All participant ask take one pioglitazone tablet time day throughout study well continue previous dose metformin sulfonylurea.. This multi-centre trial conduct Korea . The overall time participate study 25 week . Participants make 4 visit hospital endocrinologist 's office , contact telephone 7 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Inclusion Criteria Patients meeting follow criterion consider inclusion study : 1 . Institutional Review Board ( IRB ) approve write informed consent form ( ICF ) must obtain patient legally authorize representative prior trial related procedure ( include withdrawal prohibit medication , applicable ) 2 . Patients history clinical diagnosis establish type 2 diabetes mellitus define ADA criterion 2012 3 . Male female 18 80 year age 4 . Patients stable triple oral therapy metformin + sulfonylurea + pioglitazone ( ACTOS ) 15 mg ACTOSMET ( Pioglitazone 15mg/Metformin 850mg ) sulfonylurea least 12 week screen visit 5 . Patients HbA1c ≥7.0 % screen visit 6 . Patients Cpeptide ≥1.0 ng/mL screen visit 7 . Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating screen throughout duration study , 30 day last dose study medication Exclusion Criteria Patients meeting follow criterion exclude enrollment : 1 . Patients type 1 diabetes mellitus secondary form diabetes 2 . Patients treat insulin ≥7 day within 3 month prior screen visit 3 . Patients history bladder cancer patient active bladder cancer 4 . Patients history acute diabetic complication diabetic ketoacidosis 5 . Patients history acute chronic metabolic acidosis , include diabetic ketoacidosis 6 . Patients unstable rapidly progressive diabetic retinopathy , nephropathy ( estimate glomerular filtration rate [ eGFR ] &lt; 60mL/min/1.73m2 ) 7 . Patients cardiac insufficiency ( e.g. , myocardial infarction , coronary angioplasty bypass graft , unstable angina , transient ischemic attack , document cerebrovascular accident within 6 month prior screen visit ) 8 . Patients cardiac failure history cardiac failure ( New York Heart Association [ NYHA ] Stages 3 4 ) 9 . Patients serum alanine transaminase ( ALT ) level ≥2.5 time upper limit normal ( ULN ) , active liver disease , jaundice 10 . Patients take concomitant gemfibrozil strong cytochrome P450 ( CYP ) 2C8 inhibitor 11 . Patients history recurrent severe hypoglycemia 12 . Patients history hemoglobinopathy ( hemolytic anemia sickle cell disease ) may affect determination HbA1c 13 . Patients uninvestigated microscopic hematuria 14 . Patients genetic problem galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption , since study drug contains lactose 15 . Patients condition judge Investigator unsuitable study 16 . Patients use investigational experimental drug device within 60 day screen visit 17 . Lactating pregnant female . A positive pregnancy test first administration investigational medicinal product breastfeed 18 . Male patient plan father clinical trial conduct within 3 month last plan dose IMP 19 . Patients previously enrol current clinical trial 20 . The patient participate active treatment phase another clinical trial persist pharmacodynamic effect IMP clinical trial exclude 21 . Patients consider unable unwilling cooperate adequately , i.e. , follow clinical trial procedure Investigator adequately instruct ( e.g. , language difficulty , etc . ) patient anticipate available scheduled clinical trial visits/procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>